Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 2, 3 and 2 respectively.

Key Topics Covered:

  1. Introduction
  2. Microscopic Polyangiitis (MPA) Overview
  3. Therapeutics Development
  4. Pipeline Products for Microscopic Polyangiitis (MPA) - Overview
  5. Pipeline Products for Microscopic Polyangiitis (MPA) - Comparative Analysis
  6. Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies
  7. Microscopic Polyangiitis (MPA) - Therapeutics under Investigation by Universities/Institutes
  8. Microscopic Polyangiitis (MPA) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Microscopic Polyangiitis (MPA) - Products under Development by Companies
  13. Microscopic Polyangiitis (MPA) - Products under Investigation by Universities/Institutes
  14. Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
  • Celltrion Inc
  • ChemoCentryx Inc
  • Coherus BioSciences Inc
  • GlaxoSmithKline Plc
  • Panacea Biotec Ltd
  • Sandoz International GmbH
  • Teijin Pharma Ltd

For more information about this report visit http://www.researchandmarkets.com/research/pz2ndr/microscopic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs